348 related articles for article (PubMed ID: 24461063)
1. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Cocconi G; Carlini P; Gamboni A; Gasperoni S; Rodinò C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
Gallardo-Rincón D; Oñate-Ocaña LF; Calderillo-Ruiz G
Ann Surg Oncol; 2000; 7(1):45-50. PubMed ID: 10674448
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
8. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Newman E; Marcus SG; Potmesil M; Sewak S; Yee H; Sorich J; Hayek M; Muggia F; Hochster H
J Gastrointest Surg; 2002; 6(2):212-23; discussion 223. PubMed ID: 11992807
[TBL] [Abstract][Full Text] [Related]
10. [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Lu M; Shen L; Li J; Li Y; Zhang XD
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):392-5. PubMed ID: 19799092
[TBL] [Abstract][Full Text] [Related]
11. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
12. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
13. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
Guo MG; Zheng Q; Cheng Z; Wang Y; Feng CN; Yang Z
Surg Oncol; 2010 Mar; 19(1):1-3. PubMed ID: 19006661
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
Crookes P; Leichman CG; Leichman L; Tan M; Laine L; Stain S; Baranda J; Casagrande Y; Groshen S; Silberman H
Cancer; 1997 May; 79(9):1767-75. PubMed ID: 9128994
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
17. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
[TBL] [Abstract][Full Text] [Related]
18. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
[TBL] [Abstract][Full Text] [Related]
19. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
20. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
